Induction of Meningioma Stem Signature via Hydrogel Reprogramming and Application of Meningioma Stem Cell Marker CXCR4 to Pathological Diagnosis and Treatment.
Yoshitaka Oda, Masumi Tsuda, Lei Wang, Jun Suzuka, Sayaka Yuzawa, Koki Ise, Umma Habiba, Jintao He, Satoshi Tanikawa, Hirokazu Sugino, Zen-Ichi Tanei, Christian Mawrin, Jian Ping Gong, Shinya Tanaka
Biotechnology and bioengineering, 2026年02月27日, ［国際誌］
英語, 研究論文（学術雑誌）, Meningiomas account for about 40% of all primary brain tumors. How ever effective treatments for recurrent or inoperable cases remain limited. We previously demonstrated that culturing cancer cells on specific hydrogels efficiently induces cancer stem cells across multiple cancer types, a process we termed hydrogel activated reprogramming (HARP) phenomenon. In this study, we aimed to identify key molecules involved in the induction of meningioma stem cells through hydrogel-based culture. Meningioma cells cultured on hydrogels were analyzed for expression of established stem cell markers and for tumorigenicity. Microarray analysis was performed to identify meningioma stem cell specific markers and to evaluate the application of these marker molecules as a therapeutic targets or as diagnostic tools for pathological grading. Canonical stem cell markers including Nanog, and Oct3/4 were upregulated in culturing meningioma cells on hydrogels. Comprehensive gene expression analysis identified some molecules involved in cancer stem cell activity among which CXCR4 was selected as a potential therapeutic target. Stimulation of CXCR4 with its ligand CXCL12 resulted in increased expression of stem cell markers. In human meningioma pathological specimens and cultured cell lines, there was a correlation between CXCR4 expression levels and NF2 mutations and/or deletions. CXCR4 immunohistochemistry was frequently positive in cases with brain invasion along with brain invasion area. These findings suggest that CXCR4 immunohistochemistry may be useful in suggesting typical CNS WHO grade 1 meningiomas without the need for molecular analysis. We have defined meningioma stem cell signature via HARP phenomenon and identified CXCR4 with biological significance as being diagnostic target. IMPORTANCE OF THE STUDY: In addition to morphological evaluation, immunohistochemistry and genetic alteration increasingly incorporated into the diagnostic criteria for central nervous system (CNS) tumors. From the CNS WHO 5th edition onwards, epigenetic features including DNA methylation profiling, have also been adopted as diagnostic criteria. In this study, we induced epigenetic changes in meningioma cells and successfully promoted cancer stemness highlighting the potential importance of this approach for both meningioma research and meningioma diagnostic development. Furthermore, microarray analysis identified CXCR4 as a molecule consistently upregulated during stem cell induction across all three hydrogel conditions. Subsequent analysis revealed that CXCR4 immunohistochemistry may reflect the distribution of meningioma stem cells, supporting its potential utility as a diagnostic marker. By integrating basic experimental findings with histopathological evaluation of clinical specimens, this report will contribute to the advancement of meningioma research and diagnostic strategies.

Pitfall of the Diagnosis of Extramedullary Tumor: A Case of Intracranial Mesenchymal Tumor, FET::CREB Fusion‐Positive Occurring in an Atypical Clinical Setting
Yoshitaka Oda, Yoshinobu Seo, Yosuke Masumoto, Taro Mori, Takeru kuwabara, Koki Ise, Yusuke Shirai, Hirokazu Sugino, Hiromi Okada, Zen‐ichi Tanei, Lei Wang, Bunsho Asayama, Shunsuke Sato, Yasuhiro Kikuchi, Masumi Tsuda, Yoshinao Oda, Shinya Tanaka
Pathology International, Wiley, 2026年01月14日
研究論文（学術雑誌）

Multifocal rosette-forming glioneuronal tumor-like low-grade glioneuronal tumor with dysembryoplastic neuroepithelial tumor features associated with drug-resistant epilepsy: a case report and literature review.
Yuuki Ishida, Koki Ise, Kenichi Sato, Taku Asanome, Ryunosuke Yoshihara, Yoko Aburakawa, Masaki Izumi, Yoshitaka Oda, Hirokazu Sugino, Zen-Ichi Tanei, Masumi Tsuda, Shinya Tanaka
Brain tumor pathology, 2026年01月06日, ［国内誌］
英語, 研究論文（学術雑誌）, Rosette-forming glioneuronal tumors (RGNTs) are rare, World Health Organization grade 1 tumors that typically arise around the fourth ventricle. However, cerebral hemisphere RGNTs have recently been reported, with some exhibiting clinical features resembling low-grade epilepsy-associated tumor (LEAT). We report a case of multifocal RGNT in a patient with drug-refractory epilepsy. A 14-year-old woman was incidentally found to have multifocal brain tumor involving the left temporal lobe and bilateral thalamus, she developed drug-resistant epilepsy ten years later and underwent surgery. Partial tumor resection and anterior temporal lobectomy were performed. Histopathology revealed a glioneuronal tumor with oligodendroglia-like cells, neurocytic rosette, and perivascular pseudorosette, exhibiting an infiltrative growth pattern extending into the white matter. Genetic analysis revealed Fibroblast Growth Factor Receptor 1 mutation. The methylation profile analysis matched the low-grade glioneuronal tumor class but did not yield to any subclass category. Finally, the tumor was diagnosed as RGNT-like low-grade glioneuronal tumor with dysembryoplastic neuroepithelial tumor (DNT) features. Cases presenting with a LEAT-like clinical course and exhibiting histopathological features of RGNT are often difficult to definitively distinguish from DNT based on histological and genetic findings. Epilepsy-associated RGNT may harbor genetic profiles distinct from those of prototypical RGNTs, highlighting the need for further investigation.

Esophageal involvement of mantle cell lymphoma presenting with multiple lymphomatous polyposis: A single-center study.
Makoto Saito, Yoshitaka Oda, Hirokazu Sugino, Toma Suzuki, Emi Yokoyama, Minoru Kanaya, Koh Izumiyama, Akio Mori, Masanobu Morioka, Takeshi Kondo
World journal of gastrointestinal oncology, 17, 5, 105448, 105448, 2025年05月15日, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: In addition to nodal lesions, over 30% of mantle cell lymphomas (MCLs) also have gastrointestinal involvement, characteristically presenting as multiple lymphomatous polyposis (MLP), which rarely involve the esophagus. Most related papers have been case reports, and no comprehensive studies have been conducted; thus, the actual clinical situation has remained unknown for a long time. AIM: To elucidate the actual clinical situation of esophageal involvement of MCL presenting with MLP, including its prognosis. METHODS: From January 2001 to December 2021, among MCL patients whose gastrointestinal lesions were histopathologically confirmed by endoscopic biopsy at our center, 6 patients with MLP in the esophagus were selected. We retrospectively examined the clinical features of these patients, including their prognosis. RESULTS: In all patients, multiple lesions were present in the gastrointestinal tract other than the esophagus and in the lymph nodes throughout the body, and most patients also had lesions involving the bone marrow or spleen. Most of the treatments include chemotherapy, with a 50% survival period of less than 2 years and a 5-year survival rate of approximately 30%, indicating a poor prognosis. CONCLUSION: Patients with esophageal involvement of the MCL who presented with MLP had a large tumor burden and poor survival.

初発から10年以上経過して再手術が行われた毛様細胞性星細胞腫の病理学的検討　　　　　　　　　　　　　　　
伊師 雪友, 山口 秀, 宮石 陸, 岡田 宏美, 小田 義崇, 杉野 弘和, 田中 伸哉, 大木 聡悟, 小柳 泉, 藤村 幹
Brain Tumor Pathology, 42, Suppl., 101, 101, 日本脳腫瘍病理学会, 2025年05月
日本語

Utility of [18F]fluciclovine PET/MRI for identifying the optimal biopsy target region, helping to avoid underdiagnosis in patients with glioblastoma: illustrative case.
Daisuke Kawauchi, Makoto Ohno, Hirokazu Sugino, Kimiteru Ito, Kaori Fuse, Akihiko Yoshida, Yuko Kubo, Mai Honda-Kitahara, Shunsuke Yanagisawa, Takaki Ohmura, Takuma Aoki, Akiya Kawanishi, Madoka Sakuramachi, Hiroshi Igaki, Yoshitaka Narita
Journal of neurosurgery. Case lessons, 9, 9, 2025年03月03日, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Glioblastoma (GBM) is known for its significant intratumoral heterogeneity, making biopsies susceptible to underdiagnosis if samples are taken from less malignant regions. [18F]Fluciclovine, a novel PET tracer, has demonstrated high accumulation in glioma tissue, with minimal uptake in normal brain tissue. OBSERVATIONS: A 50-year-old woman presented with sensory aphasia. MRI revealed a FLAIR lesion extending from the left parietal to the medial temporal lobe. [18F]Fluciclovine PET/MRI identified two areas of increased uptake, both FLAIR negative. Stereotactic biopsy was used to obtain samples from PET-positive (PET+) and FLAIR-positive (FLAIR+) lesions. Pathological analysis of the PET+ lesion revealed densely proliferating tumor cells with irregularly enlarged nuclei, while the FLAIR+ lesion exhibited sparsely proliferating cells. Molecular analysis showed that both lesions were IDH wildtype with MGMT promoter hypomethylation. Sanger sequencing identified a telomerase reverse transcriptase promoter -124 C>T mutation in the PET+ lesion but not in the FLAIR+ lesion. The integrated diagnosis, based primarily on the PET+ lesion, was GBM, IDH wildtype. LESSONS: This case highlights the importance of [18F]fluciclovine PET/MRI in identifying high-cell-density regions, minimizing the risk of underdiagnosis in GBM. Further studies are necessary to evaluate its prognostic value in GBM management. https://thejns.org/doi/10.3171/CASE24677.

SLC13A5 plays an essential role in the energy shift to oxidative phosphorylation in cisplatin-resistant mesothelioma stem cells.
Marie Kato-Shinomiya, Hirokazu Sugino, Lei Wang, Yusuke Saito, Jintao He, Zen-Ichi Tanei, Yoshitaka Oda, Satoshi Tanikawa, Mishie Tanino, Jian Ping Gong, Masumi Tsuda, Shinya Tanaka
Pathology international, 2025年02月06日, ［国際誌］
英語, 研究論文（学術雑誌）, Mesothelioma is a highly aggressive tumor affecting an increasing number of patients worldwide. Owing to the poor clinical outcomes associated with current therapies, the development of novel therapies that target cancer stem cells (CSCs) is desirable. Here, we examined the applicability of our previously established hydrogel-based rapid CSC generation method to human mesothelioma cell lines and further analyzed the characteristics of the induced mesothelioma stem cell (MesoSC) -like cells. Human mesothelioma cell lines cultured on hydrogels presented increased expression of pan-stem cell markers and acquired spheroid formation and early tumorigenicity, suggesting that MesoSC-like cells are highly malignant. Microarray analysis demonstrated that the expression of SLC13A5, a citrate transporter involved in TCA cycle, was significantly induced in the resulting MesoSC-like cells. The overexpression of SLC13A5 resulted in a metabolic shift toward oxidative phosphorylation, increased phosphorylation of ERK and YAP, and increased SOX2 expression, leading to increased cisplatin resistance. scRNA-seq database analysis revealed that clinical mesothelioma samples contained a small number of SLC13A5-expressing cells. Our findings suggest that the hydrogel-based CSC generation method is also effective for human mesothelioma cells and that SLC13A5 may contribute to MesoSC survival. The new properties of MesoSCs revealed in this study may provide clues for establishing future treatments.

Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosis.
Yukie Ozeki, Mai Honda-Kitahara, Shunsuke Yanagisawa, Masamichi Takahashi, Makoto Ohno, Yasuji Miyakita, Miu Kikuchi, Tomoyuki Nakano, Tomohiro Hosoya, Hirokazu Sugino, Kaishi Satomi, Akihiko Yoshida, Hiroshi Igaki, Yuko Kubo, Koichi Ichimura, Hiromichi Suzuki, Kenkichi Masutomi, Akihide Kondo, Yoshitaka Narita
Japanese journal of clinical oncology, 55, 2, 106, 112, 2025年02月04日, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Isocitrate dehydrogenase-mutant astrocytoma without cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion typically follows a slow clinical course. However, some cases show early progression on magnetic resonance imaging, and these characteristics remain under-reported. This study aimed to elucidate the characteristics of isocitrate dehydrogenase-mutant astrocytoma showing early progression on magnetic resonance imaging. METHODS: This retrospective study included 52 cases of primary astrocytoma, isocitrate dehydrogenase-mutant, Central Nervous System (CNS) 5 World Health Organization grade 2-3 according to the World Health Organization 2021 classification. Patients underwent surgery followed by radiation therapy and/or chemotherapy at our institution from 2006 to 2019. Progression-free survival and overall survival were analyzed. RESULTS: There were 24 and 28 grade 2 and grade 3 astrocytomas, respectively. The median patient age was 38 years. Forty-three patients underwent radiotherapy. Progression was diagnosed by magnetic resonance imaging in 22 patients with initial radiotherapy. Thirteen of the 22 patients underwent surgery, and seven of the 13 patients received surgery within 24 months of the initial radiotherapy. Histopathologically, radiation necrosis was confirmed in four of these seven patients (57.1%). The true progression-free survival rate, excluding radiation necrosis, at 2 years after surgery was 91.3% for grade 2 astrocytoma and 88.5% for grade 3 astrocytoma. The 5-year overall survival rate was 85.7% for grade 2 tumours and 76.4% for grade 3 tumours. CONCLUSIONS: Radiation necrosis should be considered in cases showing early progression of isocitrate dehydrogenase-mutant astrocytoma, and a second surgery should be performed to confirm true recurrence or radiation necrosis. Astrocytomas with telomerase reverse-transcriptase promoter mutations may relapse relatively early and should be followed up with caution.

【膵胆道周囲の後腹膜腫瘤性病変の診断と治療】膵胆道周囲の後腹膜腫瘍の病理
杉野 弘和, 吉田 朗彦
胆と膵, 45, 9, 881, 888, 医学図書出版(株), 2024年09月
日本語

Novel case of anastomosing hemangioma of the extradural space: illustrative case.
Shohei Fujita, Makoto Ohno, Shuhei Osaki, Hirokazu Sugino, Akihiko Yoshida, Masamichi Takahashi, Shunsuke Yanagisawa, Sho Osawa, Takahiro Tsuchiya, Yoshitaka Narita
Journal of neurosurgery. Case lessons, 8, 9, 2024年08月26日, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Anastomosing hemangiomas are benign vascular neoplasms occurring mainly in the genitourinary tract and paraspinal soft tissues. There have been no reported cases of anastomosing hemangiomas occurring in the spinal epidural space; therefore, their clinical and radiological presentations remain unclear. OBSERVATIONS: A 55-year-old man presented with progressive back pain and motor and sensory disturbances in both lower extremities. Magnetic resonance imaging (MRI) revealed an extradural lesion at the T4-6 level that extended into the extraspinal region through the left T5-6 intervertebral foramen. Axial MRI revealed that the tumor encircled the spinal cord, with sharp horn-like ends in the intraspinal canal. The patient underwent complete tumor resection with T4-6 laminectomy and left T5-6 foraminotomy. The histopathological diagnosis was an anastomo-sing hemangioma exhibiting anastomosing proliferation of capillary vessels with hobnailed endothelial cells. His symptoms improved, and tumor control was achieved 4 months after surgery without adjuvant therapy. LESSONS: Although rare, anastomosing hemangiomas can occur in the spinal epidural space. Radiologically, the tumors show horn-like projections encircling the spinal cord, which can be diagnostic cues. Anastomosing hemangiomas should be included in the differential diagnosis of spinal epidural tumors, especially when characteristic horn-like projections are present. https://thejns.org/doi/10.3171/CASE24265.

Pediatric atypical teratoid/rhabdoid tumor in the cauda equina with rapid tumor progression: illustrative case.
Takahiro Tsuchiya, Makoto Ohno, Yuko Watanabe, Shohei Fujita, Bunpei Miyazaki, Hirokazu Sugino, Hiroshi Igaki, Akihiko Yoshida, Masamichi Takahashi, Shunsuke Yanagisawa, Sho Osawa, Chitose Ogawa, Yoshitaka Narita
Journal of neurosurgery. Case lessons, 8, 7, 2024年08月12日, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Atypical teratoid/rhabdoid tumor (AT/RT) is an uncommon malignant neoplasm and rarely occurs in the spinal space, especially in the cauda equina. Only 8 cases of pediatric AT/RT of the cauda equina have been reported. Therefore, its clinical behavior and optimal treatment remain unclear. OBSERVATIONS: The authors describe the case of a 9-year-old boy who presented with progressive back and left leg pain. Initial magnetic resonance imaging showed an intradural extramedullary lesion at the L3-4 level, which progressed rapidly to the L2-5 level within a month. He underwent partial resection of the tumor with an L2-5 laminectomy. The histopathological diagnosis was AT/RT. He received adjuvant chemotherapy and radiotherapy, and his gait disturbance improved postoperatively. At 6 months' follow-up, disease recurrence was not observed. LESSONS: Although extremely rare, AT/RT should be included in the differential diagnosis for prompt therapeutic intervention. Safe resection with minimal functional impairment, followed by postoperative chemoradiation, can lead to tumor control and improve neurological function. https://thejns.org/doi/10.3171/CASE24219.

Resection and postoperative pazopanib for intraspinal recurrent solitary fibrous tumor: illustrative case.
Makoto Ohno, Yuki Kawaguchi, Hirokazu Sugino, Akihiko Yoshida, Masamichi Takahashi, Shunsuke Yanagisawa, Sho Osawa, Takahiro Tsuchiya, Shohei Fujita, Yoshitaka Narita
Journal of neurosurgery. Case lessons, 8, 5, 2024年07月29日, ［国際誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Intracranial solitary fibrous tumors (SFTs) rarely recur in the spinal space. Only 4 cases of spinal recurrence from intracranial SFT have been reported; therefore, the optimal treatment of recurrent spinal SFT remains unclear. OBSERVATIONS: A 53-year-old woman with a history of resection of a right occipital anaplastic SFT presented with progressive back and side pain. She was diagnosed with an intradural extramedullary tumor ventral to the spinal cord at the T5-7 level. She underwent tumor resection with T5-6 laminectomy and T4 and T7 partial laminectomy. The tumor was completely removed in a piecemeal fashion using an ultrasonic aspirator with careful control of bleeding. Her symptoms quickly improved after the surgery, and she returned to normal life. The tumor was diagnosed as SFT. Pazopanib was administered postoperatively. Despite the recurrence of the intracranial tumor, the patient was alive without recurrence of the spinal tumor 14 months after resection. LESSONS: Although rare, intracranial SFTs have a risk of spinal recurrence. Complete resection of a recurrent spinal SFT can be achieved even in the ventral location. Pazopanib could be a possible therapeutic option for preventing local tumor recurrence in the management of recurrent spinal SFT. https://thejns.org/doi/10.3171/CASE24217.

An autopsy case of pulmonary tumor thrombotic microangiopathy that developed during chemotherapy for salivary duct carcinoma of the parotid gland.
Mai Itoyama, Akihiro Ohara, Kazuki Yokoyama, Shun Yamamoto, Ken Kato, Yuichiro Tada, Ayumi Sugitani, Hirokazu Sugino, Yasushi Yatabe, Masahiko Kusumoto, Kenichi Nakamura, Yoshitaka Honma
Auris, nasus, larynx, 51, 5, 829, 833, 2024年07月23日, ［国際誌］
英語, 研究論文（学術雑誌）, Pulmonary tumor thrombotic microangiopathy (PTTM) is a rapidly progressive cancer-related disease with a dismal clinical course. The patient in this report was a 43-year-old man with metastatic salivary duct carcinoma arising from the parotid gland. Combined androgen blockade therapy was administered started as first-line treatment, but failed after 5 months, followed by docetaxel plus carboplatin therapy as second-line treatment, which failed after 3 months. Genomic profiling revealed a BRAF V600E mutation, and combined BRAF and MEK inhibitor therapy was started as third-line treatment. The cancer remained stable during the first 10 months of third-line treatment, but treatment was subsequently discontinued due to the onset of symptoms of fatigue, myalgia and arthritis. Twenty days after the onset of these symptoms and interruption of third-line treatment, the patient was urgently admitted to hospital with respiratory distress and severe thrombocytopenia. CT images at the time of admission led our radiologist to the possibility of PTTM, but the patient died the day after admission and autopsy findings indicated that PTTM was the cause of death. This report describes a very informative case of PTTM with sequential imaging and detailed autopsy findings were available and provides a literature review.

MUC5AC immunoreactivity in scattered tumor cells is useful for diagnosing CIC-rearranged sarcoma.
Shogo Nishino, Naoki Kojima, Hirokazu Sugino, Taisuke Mori, Yasushi Yatabe, Akihiko Yoshida
Virchows Archiv : an international journal of pathology, 2024年07月06日, ［国際誌］
英語, 研究論文（学術雑誌）, CIC-rearranged sarcoma is an aggressive round cell sarcoma, and an alternative ATXN1/ATXN1L fusion has been reported. Diagnosis may be difficult, and molecular assays may suffer from imperfect sensitivity. Characteristic histology and ETV4 immunohistochemical positivity are diagnostically helpful. However, ETV4 staining is unavailable in most laboratories. Here, we explored the diagnostic utility of MUC5AC immunohistochemistry in CIC-rearranged sarcomas. All 30 cases, except one, of CIC-rearranged sarcomas and 2 ATXN1-rearranged sarcomas were positive for MUC5AC, although the number of immunopositive cells was generally low (< 5%) in most samples, representing a characteristic scattered pattern. The only MUC5AC-negative case had the lowest tumor volume. Among the 110 mimicking round cell malignancies, 12 tumors showed MUC5AC positivity, including occasional cases of synovial sarcoma and small cell carcinoma, whereas the remaining 98 samples were negative. Despite its lower specificity than that of ETV4 and sparse reactivity that requires careful interpretation, MUC5AC may serve as a useful marker for CIC/ATXN1-rearranged sarcoma because of its wider accessibility.

Successful treatment of pediatric patients with high-grade gliomas featuring leptomeningeal metastases by targeting BRAF V600E mutations with dabrafenib plus trametinib: two illustrative cases.
Yuki Kawaguchi, Yuko Watanabe, Yasuji Miyakita, Makoto Ohno, Chitose Ogawa, Masamichi Takahashi, Shunsuke Yanagisawa, Takayuki Mukai, Hiroshi Igaki, Hirokazu Sugino, Akihiko Yoshida, Yoshitaka Narita
International cancer conference journal, 13, 3, 256, 262, 2024年07月, ［国際誌］
英語, 研究論文（学術雑誌）, A combination of BRAF and MEK inhibitors is reported to be effective for gliomas with the BRAF V600E mutation; however, its efficacy in gliomas with leptomeningeal metastases (LMM) is still unknown. In this report, we describe two pediatric patients with high-grade glioma featuring the BRAF V600E mutation who were treated with dabrafenib and trametinib for LMM. Both 2 cases underwent craniotomy for primary intracranial lesions and were diagnosed as a high-grade glioma with BRAF V600E mutation; one case was consistent with anaplastic pleomorphic xanthoastorocytoma, the other was epithelioid glioblastoma. They received standard treatment for the lesions but subsequently were found to have new lesions including multiple spinal dissemination. We started administering dabrafenib and trametinib. Within a few days of starting treatment, the symptoms improved dramatically and MRI performed one month after the prescription of the two drugs demonstrated remission of both brain and spinal lesions. This report shows that dabrafenib and trametinib are effective not only for recurrent lesions but also for LMM in pediatric patients.

WHO新分類(WHO2021)の課題とその克服1:脳腫瘍病理形態診断と分子診断の融合の可能性 WHO分類第5版における分子診断の臨床的有用性　　　　　　　　　　　　　　　
大野 誠, 中島 拓真, 杉野 弘和, 高橋 雅道, 柳澤 俊介, 大澤 祥, 土屋 貴裕, 吉田 朗彦, 鈴木 啓道, 成田 善孝
Brain Tumor Pathology, 41, Suppl., 075, 075, 日本脳腫瘍病理学会, 2024年05月
日本語

術後放射線化学療法が有用であった成人DICER1 associated CNS sarcomaの一例　　　　　　　　　　　　　　　
藤田 昇平, 大野 誠, 杉野 弘和, 高橋 雅道, 柳澤 俊介, 大澤 祥, 土屋 貴裕, 吉田 朗彦, 成田 善孝
Brain Tumor Pathology, 41, Suppl., 151, 151, 日本脳腫瘍病理学会, 2024年05月
日本語

CIC-rearranged sarcomaと類似し、ATXN1遺伝子再構成を伴う小脳腫瘍の一例　　　　　　　　　　　　　　　
丸山 隆志, 井上 瑞穂, 柳澤 俊介, 杉野 弘和, 吉田 朗彦, 成田 善孝, 横尾 英明, 金 彪
Brain Tumor Pathology, 41, Suppl., 171, 171, 日本脳腫瘍病理学会, 2024年05月
日本語

WHO新分類(WHO2021)の課題とその克服1:脳腫瘍病理形態診断と分子診断の融合の可能性 WHO分類第5版における分子診断の臨床的有用性　　　　　　　　　　　　　　　
大野 誠, 中島 拓真, 杉野 弘和, 高橋 雅道, 柳澤 俊介, 大澤 祥, 土屋 貴裕, 吉田 朗彦, 鈴木 啓道, 成田 善孝
Brain Tumor Pathology, 41, Suppl., 075, 075, 日本脳腫瘍病理学会, 2024年05月
日本語

術後放射線化学療法が有用であった成人DICER1 associated CNS sarcomaの一例　　　　　　　　　　　　　　　
藤田 昇平, 大野 誠, 杉野 弘和, 高橋 雅道, 柳澤 俊介, 大澤 祥, 土屋 貴裕, 吉田 朗彦, 成田 善孝
Brain Tumor Pathology, 41, Suppl., 151, 151, 日本脳腫瘍病理学会, 2024年05月
日本語

CIC-rearranged sarcomaと類似し、ATXN1遺伝子再構成を伴う小脳腫瘍の一例　　　　　　　　　　　　　　　
丸山 隆志, 井上 瑞穂, 柳澤 俊介, 杉野 弘和, 吉田 朗彦, 成田 善孝, 横尾 英明, 金 彪
Brain Tumor Pathology, 41, Suppl., 171, 171, 日本脳腫瘍病理学会, 2024年05月
日本語

The development of a custom RNA-sequencing panel for the identification of predictive and diagnostic biomarkers in glioma.
Yukina Shirai, Toshihide Ueno, Shinya Kojima, Hiroshi Ikeuchi, Rina Kitada, Takafumi Koyama, Fumiyuki Takahashi, Kazuhisa Takahashi, Koichi Ichimura, Akihiko Yoshida, Hirokazu Sugino, Hiroyuki Mano, Yoshitaka Narita, Masamichi Takahashi, Shinji Kohsaka
Journal of neuro-oncology, 2024年02月16日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, PURPOSE: Various molecular profiles are needed to classify malignant brain tumors, including gliomas, based on the latest classification criteria of the World Health Organization, and their poor prognosis necessitates new therapeutic targets. The Todai OncoPanel 2 RNA Panel (TOP2-RNA) is a custom-target RNA-sequencing (RNA-seq) using the junction capture method to maximize the sensitivity of detecting 455 fusion gene transcripts and analyze the expression profiles of 1,390 genes. This study aimed to classify gliomas and identify their molecular targets using TOP2-RNA. METHODS: A total of 124 frozen samples of malignant gliomas were subjected to TOP2-RNA for classification based on their molecular profiles and the identification of molecular targets. RESULTS: Among 55 glioblastoma cases, gene fusions were detected in 11 cases (20%), including novel MET fusions. Seven tyrosine kinase genes were found to be overexpressed in 15 cases (27.3%). In contrast to isocitrate dehydrogenase (IDH) wild-type glioblastoma, IDH-mutant tumors, including astrocytomas and oligodendrogliomas, barely harbor fusion genes or gene overexpression. Of the 34 overexpressed tyrosine kinase genes, MDM2 and CDK4 in glioblastoma, 22 copy number amplifications (64.7%) were observed. When comparing astrocytomas and oligodendrogliomas in gene set enrichment analysis, the gene sets related to 1p36 and 19q were highly enriched in astrocytomas, suggesting that regional genomic DNA copy number alterations can be evaluated by gene expression analysis. CONCLUSIONS: TOP2-RNA is a highly sensitive assay for detecting fusion genes, exon skipping, and aberrant gene expression. Alterations in targetable driver genes were identified in more than 50% of glioblastoma. Molecular profiling by TOP2-RNA provides ample predictive, prognostic, and diagnostic biomarkers that may not be identified by conventional assays and, therefore, is expected to increase treatment options for individual patients with glioma.

Development of a rapid and comprehensive genomic profiling test supporting diagnosis and research for gliomas.
Takuma Nakashima, Ryo Yamamoto, Makoto Ohno, Hirokazu Sugino, Masamichi Takahashi, Yusuke Funakoshi, Shohei Nambu, Atsuhito Uneda, Shunsuke Yanagisawa, Takeo Uzuka, Yoshiki Arakawa, Ryosuke Hanaya, Joji Ishida, Koji Yoshimoto, Ryuta Saito, Yoshitaka Narita, Hiromichi Suzuki
Brain tumor pathology, 2024年02月08日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, A prompt and reliable molecular diagnosis for brain tumors has become crucial in precision medicine. While Comprehensive Genomic Profiling (CGP) has become feasible, there remains room for enhancement in brain tumor diagnosis due to the partial lack of essential genes and limitations in broad copy number analysis. In addition, the long turnaround time of commercially available CGPs poses an additional obstacle to the timely implementation of results in clinics. To address these challenges, we developed a CGP encompassing 113 genes, genome-wide copy number changes, and MGMT promoter methylation. Our CGP incorporates not only diagnostic genes but also supplementary genes valuable for research. Our CGP enables us to simultaneous identification of mutations, gene fusions, focal and broad copy number alterations, and MGMT promoter methylation status, with results delivered within a minimum of 4 days. Validation of our CGP, through comparisons with whole-genome sequencing, RNA sequencing, and pyrosequencing, has certified its accuracy and reliability. We applied our CGP for 23 consecutive cases of intracranial mass lesions, which demonstrated its efficacy in aiding diagnosis and prognostication. Our CGP offers a comprehensive and rapid molecular profiling for gliomas, which could potentially apply to clinical practices and research primarily in the field of brain tumors.

Prognostic impact of HER2-low positivity in patients with HR-positive, HER2-negative, node-positive early breast cancer.
Shohei Shikata, Takeshi Murata, Masayuki Yoshida, Hiromi Hashiguchi, Yukiko Yoshii, Ayumi Ogawa, Chikashi Watase, Sho Shiino, Hirokazu Sugino, Kenjiro Jimbo, Akiko Maeshima, Eriko Iwamoto, Shin Takayama, Akihiko Suto
Scientific reports, 13, 1, 19669, 19669, 2023年11月11日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Adjuvant therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer (EBC) remains challenging. The prognostic significance of HER2-low positivity in these patients is not fully understood. In our retrospective study, we analyzed 647 patients with HR-positive, HER2-negative, node-positive EBC, stratifying them into three cohorts based on axillary lymph node involvement, tumor size, and characteristics. Cohort 1 included patients with either ≥ 4 positive axillary lymph nodes or 1-3 positive nodes with histological grade 3 or tumor size ≥ 5 cm. Cohort 2 consisted of patients with 1-3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 ≥ 20%. Cohort 3 comprised patients with 1-3 positive nodes, histological grade < 3, tumor size < 5 cm, and Ki-67 < 20%. We compared invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) between HER2-low (IHC1+ or IHC2+/FISH-) and HER2-zero (IHC0) groups in each cohort. In cohort 1, HER2-low patients exhibited significantly better 5-year IDFS (84.2% vs. 73.6%, p = 0.0213) and DRFS (88.2% vs. 79.8%, p = 0.0154). However, no significant differences were observed in cohorts 2 and 3. Our findings suggest HER2-low positivity as a prognostic factor in HR-positive, HER2-negative, and node-positive EBC.

Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.
Takeshi Murata, Masayuki Yoshida, Sho Shiino, Chikashi Watase, Ayumi Ogawa, Shohei Shikata, Hiromi Hashiguchi, Yukiko Yoshii, Hirokazu Sugino, Kenjiro Jimbo, Akiko Maeshima, Eriko Iwamoto, Shin Takayama, Akihiko Suto
Breast cancer (Tokyo, Japan), 30, 6, 1054, 1064, 2023年11月, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）, BACKGROUND: Histological grade (HG) has been used in the MonrachE trial to select patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive high-risk early breast cancer (EBC). Although nuclear grade (NG) is widely used in Japan, it is still unclear whether replacing HG with NG can appropriately select high-risk patients. METHODS: We retrospectively reviewed 647 patients with HR-positive, HER2-negative, node-positive EBC and classified them into the following four groups: group 1: ≥ 4 positive axillary lymph nodes (pALNs) or 1-3 pALNs and either grade 3 of both grading systems or tumors ≥ 5 cm; group 2: 1-3 pALNs, grade < 3, tumor < 5 cm, and Ki-67 ≥ 20%; group 3: 1-3 pALNs, grade < 3, tumor < 5 cm, and Ki-67 < 20%; and group 4: group 2 or 3 by HG classification but group 1 by NG classification. We compared invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) among the four groups using the Kaplan-Meier method with the log-rank test. RESULTS: Group 1 had a significantly worse 5-year IDFS and DRFS than groups 2 and 3 (IDFS 80.8% vs. 89.5%, P = 0.0319, 80.8% vs. 95.5%, P = 0.002; DRFS 85.2% vs. 95.3%, P = 0.0025, 85.2% vs. 98.4%, P < 0.001, respectively). Group 4 also had a significantly worse 5-year IDFS (78.0%) and DRFS (83.6%) than groups 2 and 3. CONCLUSIONS: NG was useful for stratifying the risk of recurrence in patients with HR-positive, HER2-negative, node-positive EBC and was the appropriate risk assessment for patient groups not considered high-risk by HG classification.

A Case of Uterine Tumor Resembling Ovarian Sex Cord Tumor With Prominent Myxoid Features.
Koki Ise, Zen-Ichi Tanei, Yoshitaka Oda, Satoshi Tanikawa, Hirokazu Sugino, Yusuke Ishida, Masumi Tsuda, Yuko Gotoda, Kunihiko Nishiwaki, Hiroyuki Yanai, Tadashi Hasegawa, Kazuo Nagashima, Shinya Tanaka
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2023年06月14日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, Uterine tumor resembling ovarian sex cord tumor (UTROSCT) is a rare tumor with low malignant potential that commonly occurs in middle age. Although more than 100 cases have been reported to date, myxoid morphology is not well documented. Here, we present a 75-yr-old woman with abnormal vaginal bleeding, with an 8-cm mass in the uterine corpus detected by irregular, high-intensity signaling on T2-weighted imaging. The uterine mass had a glistening mucinous appearance on gross examination. Microscopically, most of the tumor cells were floating in the myxoid stroma. The tumor cells formed clusters or nests with abundant cytoplasm, while some exhibited trabecular or rhabdoid appearances. Immunohistochemically, tumor cells were positive for pancytokeratin (AE1/AE3), α-smooth muscle actin, CD10, progesterone receptor, and some sex cord markers such as calretinin, inhibin, CD56, steroidogenic factor-1. Electron microscopy demonstrated epithelial and sex cord differentiation. This tumor was negative for JAZF1-JJAZ1 fusion gene that is frequently found in low-grade endometrial stromal sarcoma. Fusion genes related to UTROSCT, including NCOA2/3, were not detected by reverse transcription polymerase chain reaction. The present case suggests that UTROSCT should be included in the differential diagnosis of myxoid uterine tumors.

High-grade neuroepithelial tumor with EP300::BCOR fusion and negative BCOR immunohistochemical expression: a case report.
Hirokazu Sugino, Kaishi Satomi, Taisuke Mori, Yuuki Mukai, Mai Honda-Kitahara, Yuko Matsushita, Koichi Ichimura, Yoshitaka Narita, Akihiko Yoshida
Brain tumor pathology, 2023年02月22日, ［査読有り］, ［筆頭著者］, ［国内誌］
英語, 研究論文（学術雑誌）, In the World Health Organization tumor classification (fifth edition), central nervous system (CNS) tumors with BCOR internal tandem duplications have been recognized as a new tumor type. Some recent studies have reported CNS tumors with EP300::BCOR fusions, predominantly in children and young adults, expanding the spectrum of BCOR-altered CNS tumors. This study reports a new case of high-grade neuroepithelial tumor (HGNET) with an EP300::BCOR fusion in the occipital lobe of a 32-year-old female. The tumor displayed anaplastic ependymoma-like morphologies characterized by a relatively well-circumscribed solid growth with perivascular pseudorosettes and branching capillaries. Immunohistochemically, OLIG2 was focally positive and BCOR was negative. RNA sequencing revealed an EP300::BCOR fusion. The Deutsches Krebsforschungszentrum DNA methylation classifier (v12.5) classified the tumor as CNS tumor with BCOR/BCORL1 fusion. The t-distributed stochastic neighbor embedding analysis plotted the tumor close to the HGNET with BCOR alteration reference samples. BCOR/BCORL1-altered tumors should be included in the differential diagnosis of supratentorial CNS tumors with ependymoma-like histological features, especially when they lack ZFTA fusion or express OLIG2 even in the absence of BCOR expression. Analysis of published CNS tumors with BCOR/BCORL1 fusions revealed partly overlapping but not identical phenotypes. Further studies of additional cases are required to establish their classification.

Keratin-positive fibrotic extraskeletal myxoid chondrosarcoma: a close mimic of myoepithelial tumor.
Hirokazu Sugino, Shintaro Iwata, Kaishi Satomi, Taisuke Mori, Sumihito Nobusawa, Toshiteru Nagashima, Yuko Matsushita, Yasushi Yatabe, Koichi Ichimura, Akira Kawai, Akihiko Yoshida
Histopathology, 82, 6, 937, 945, 2023年02月08日, ［査読有り］, ［筆頭著者］, ［国際誌］
英語, 研究論文（学術雑誌）, AIMS: Extraskeletal myxoid chondrosarcoma (EMC) is a rare form of adult sarcoma with distinct histology and NR4A3 gene fusion. Immunohistochemically, EMCs are variably positive for S100 protein and neuroendocrine markers. Unlike histologically similar soft-tissue myoepithelial tumors, keratin expression is rare. Prompted by two recent EMC cases with diffuse keratin expression, we investigated the expression of epithelial markers in a molecularly confirmed cohort of EMC and identified two additional similar cases. METHODS AND RESULTS: Four keratin-positive EMCs occurred in one man and three women aged 46-59 years. All tumors displayed non-classic histology with prominent stromal fibrosis, and keratin AE1/AE3 was expressed either diffusely (N = 2) or focally (N = 2). In one tumor, keratin expression was limited to the sclerotic area. All tumors co-expressed epithelial membrane antigen and two additionally expressed S100 protein or glial fibrillary acidic protein. All tumors harbored NR4A3 fusions including TAF15::NR4A3 (N = 1) and EWSR1::NR4A3 (N = 3). Two cases were initially considered as most consistent with myoepithelial tumors based on widespread stromal fibrosis and keratin expression. DNA methylation analysis classified two tumors tested as EMCs. CONCLUSIONS: We identified a small subset of EMCs characterized by keratin expression and prominent stromal fibrosis. This histological pattern must be recognized in the differential diagnosis of myoepithelial tumors because misclassification may lead to the erroneous prediction of tumor behavior and may alter patient management. NR4A3 genetic analysis should be considered even in the face of keratin expression and prominent stromal fibrosis.

Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.
Tomomi Sanomachi, Hitomi Sumiyoshi Okuma, Rui Kitadai, Asuka Kawachi, Shu Yazaki, Momoko Tokura, Motoko Arakaki, Ayumi Saito, Shosuke Kita, Kasumi Yamamoto, Aiko Maejima, Yuki Kojima, Tadaaki Nishikawa, Kazuki Sudo, Tatsunori Shimoi, Emi Noguchi, Yasuhiro Fujiwara, Hirokazu Sugino, Sho Shiino, Akihiko Suto, Masayuki Yoshida, Kan Yonemori
Frontiers in oncology, 13, 1157789, 1157789, 2023年, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）, INTRODUCTION: Triple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data is scarce. In recent years, it has been reported that HER2-low cases (1+/2+ and in situ hybridization negative) have different prognoses than HER2-0 cases. However, the risk of recurrence and risk factors in this HER2-low population for stage I TNBC have not yet been investigated. METHODS: Herein, out of 174 patients with TNBC who underwent surgery from June 2004 to December 2009 at the National Cancer Center Hospital (Tokyo), we retrospectively examined 42 cases diagnosed as T1N0M0 TNBC after excluding those treated with preoperative chemotherapy. RESULTS: All patients were female, the median age was 60.5 years, and 11 cases were HER2-low and 31 cases were HER2-0. The median follow-up period was 121 months. Postoperative adjuvant therapy was administered in 30 patients and recurrence occurred in 8 patients. HER2-low cases showed a significantly shorter disease-free survival (HR: 7.0; 95% CI: 1.2- 40.2; P=0.0016) and a trend towards shorter overall survival (hazard ratio [HR]: 4.2, 95% confidence interval [CI]: 0.58-31.4) compared with that of HER2-0 cases. HER2 was also identified as a factor for poor prognosis from the point- estimated values in univariate and multivariate analyses after confirming that there was no correlation between the other factors. CONCLUSION: For patients with stage I TNBC, the HER2-low population had a significantly worse prognosis than the HER2-0 population.

Deep fibrous histiocytoma of the index finger: a case report.
Hiroki Shibayama, Yuichiro Matsui, Daisuke Kawamura, Daisuke Momma, Takeshi Endo, Yuki Matsui, Yasutaka Yawaka, Kanako C Hatanaka, Emi Takakuwa, Hirokazu Sugino, Yutaka Hatanaka, Tadashi Hasegawa, Norimasa Iwasaki
Case reports in plastic surgery & hand surgery, 10, 1, 2207637, 2207637, 2023年, ［査読有り］, ［国際誌］
英語, Our patient presented with an elastic soft mass of his left index finger. Hematoxylin and eosin staining showed a high cellular density with spindle-shaped cells in a storiform pattern. Immunohistochemical staining was positive for CD68, factor XIIIa and α-smooth muscle actin, and negative for CD34, STAT6, S100 protein, and desmin.

An autopsy case report of adult‐onset Krabbe disease: Comparison with an infantile‐onset case
Miu Sasaki, Miori Ebata, Zen‐ichi Tanei, Yoshitaka Oda, Akiko Hamauchi, Satoshi Tanikawa, Hirokazu Sugino, Yusuke Ishida, Takenori Abe, Nobutaka Arai, Kazuya Sako, Shinya Tanaka
Pathology International, 2022年10月06日, ［査読有り］
英語, 研究論文（学術雑誌）

Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas
Kaishi Satomi, Akihiko Yoshida, Yuko Matsushita, Hirokazu Sugino, Kenji Fujimoto, Mai Honda-Kitahara, Masamichi Takahashi, Makoto Ohno, Yasuji Miyakita, Yoshitaka Narita, Yasushi Yatabe, Junji Shibahara, Koichi Ichimura
Brain Tumor Pathology, 39, 4, 210, 217, 2022年10月, ［査読有り］
英語, 研究論文（学術雑誌）

Duodenal-type follicular lymphoma more than 10 years after treatment intervention: A retrospective single-center analysis
Makoto Saito, Akio Mori, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Masanobu Morioka, Takeshi Kondo, Hirokazu Sugino
World Journal of Gastrointestinal Oncology, 14, 8, 1552, 1561, 2022年08月15日, ［査読有り］
英語, 研究論文（学術雑誌）

Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma
Shunji Sano, Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Akihisa Nagatsu, Takeshi Aiyama, Keizo Kazui, Hiroki Shomura, Shinya Ueki, Yuzuru Sakamoto, Chisato Shirakawa, Hirofumi Kamachi, Hirokazu Sugino, Tomoko Mitsuhashi, Akinobu Taketomi
INTERNATIONAL CANCER CONFERENCE JOURNAL, 2022年08月, ［査読有り］
英語, 研究論文（学術雑誌）

Novel rapid immunohistochemistry using an alternating current electric field identifies Rac and Cdc42 activation in human colon cancer FFPE tissues.
Masumi Tsuda, Runa Horio, Lei Wang, Tomoko Takenami, Jun Moriya, Jun Suzuka, Hirokazu Sugino, Zenichi Tanei, Mishie Tanino, Shinya Tanaka
Scientific reports, 12, 1, 1733, 1733, 2022年02月02日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Combination of ultra-purified stem cells with an in situ-forming bioresorbable gel enhances intervertebral disc regeneration
Daisuke Ukeba, Katsuhisa Yamada, Takashi Suyama, Darren R. Lebl, Takeru Tsujimoto, Takayuki Nonoyama, Hirokazu Sugino, Norimasa Iwasaki, Masatoki Watanabe, Yumi Matsuzaki, Hideki Sudo
eBioMedicine, 76, 103845, 103845, 2022年02月, ［査読有り］
英語, 研究論文（学術雑誌）

Multiple Colorectal Mucosa-Associated Lymphoid Tissue Lymphoma Successfully Treated with Chemotherapy
Makoto Saito, Shihori Tsukamoto, Takashi Ishio, Emi Yokoyama, Koh Izumiyama, Akio Mori, Masanobu Morioka, Takeshi Kondo, Hirokazu Sugino
Case Reports in Oncology, 14, 3, 1761, 1767, 2021年12月13日, ［査読有り］
英語, 研究論文（学術雑誌）

ハイドロゲルを用いた新規髄膜腫治療標的分子の検討(Analysis of novel therapeutic target for meningioma using hydrogel)　　　　　　　　　　　　　　　
小田 義崇, 津田 真寿美, 湯澤 明夏, 王 磊, Umma Habiba, 杉野 弘和, 種井 善一, グン 剣萍, 田中 伸哉
日本病理学会会誌, 110, 2, 110, 110, (一社)日本病理学会, 2021年10月
英語

Rapid reprogramming of tumour cells into cancer stem cells on double-network hydrogels.
Jun Suzuka, Masumi Tsuda, Lei Wang, Shinji Kohsaka, Karin Kishida, Shingo Semba, Hirokazu Sugino, Sachiyo Aburatani, Martin Frauenlob, Takayuki Kurokawa, Shinya Kojima, Toshihide Ueno, Yoshihiro Ohmiya, Hiroyuki Mano, Kazunori Yasuda, Jian Ping Gong, Shinya Tanaka
Nature biomedical engineering, 5, 8, 914, 925, 2021年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Arid5a Promotes Immune Evasion by Augmenting Tryptophan Metabolism and Chemokine Expression.
Gyanu Parajuli, Murat Tekguc, James B Wing, Ari Hashimoto, Daisuke Okuzaki, Takeshi Hirata, Atsushi Sasaki, Takahide Itokazu, Haruka Handa, Hirokazu Sugino, Yoshihiro Nishikawa, Hozaifa Metwally, Yuzo Kodama, Shinya Tanaka, Hisataka Sabe, Toshihide Yamashita, Shimon Sakaguchi, Tadamitsu Kishimoto, Shigeru Hashimoto
Cancer immunology research, 9, 8, 862, 876, 2021年08月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Umma Habiba, Hirokazu Sugino, Roumyana Yordanova, Koki Ise, Zen-Ichi Tanei, Yusuke Ishida, Satoshi Tanikawa, Shunsuke Terasaka, Ken-Ichi Sato, Yuuta Kamoshima, Masahiko Katoh, Motoo Nagane, Junji Shibahara, Masumi Tsuda, Shinya Tanaka
Acta neuropathologica communications, 9, 1, 95, 95, 2021年05月21日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Successful management of a patient with active Cushing's disease complicated with coronavirus disease 2019 (COVID-19) pneumonia.
Akiko Yuno, Yoshiyuki Kenmotsu, Yuka Takahashi, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Akinobu Nakamura, Yu Yamashita, Junichi Nakamura, Sho Nakakubo, Keisuke Kamada, Masaru Suzuki, Hirokazu Sugino, Naoko Inoshita, Satoshi Konno, Hideaki Miyoshi, Tatsuya Atsumi, Yutaka Sawamura, Akira Shimatsu
Endocrine journal, 68, 4, 477, 484, 2021年04月28日, ［査読有り］, ［国内誌］
英語, 研究論文（学術雑誌）

ハイドロゲルによる癌幹細胞性の誘導を利用した髄膜腫の新規治療標的分子の検索　　　　　　　　　　　　　　　
小田 義崇, 津田 真寿美, 湯澤 明夏, 王 磊, 杉野 弘和, 鈴鹿 淳, グン 剣萍, 田中 伸哉
日本病理学会会誌, 110, 1, 225, 225, (一社)日本病理学会, 2021年03月
日本語

Signaling adaptor protein Crk is involved in malignant feature of pancreatic cancer associated with phosphorylation of c-Met.
Satoko Uemura, Lei Wang, Masumi Tsuda, Jun Suzuka, Satoshi Tanikawa, Hirokazu Sugino, Toru Nakamura, Tomoko Mitsuhashi, Satoshi Hirano, Shinya Tanaka
Biochemical and biophysical research communications, 524, 2, 378, 384, 2020年04月02日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

ハイドロゲルを用いた髄膜腫治療標的分子の検索　　　　　　　　　　　　　　　
小田 義崇, 津田 真寿美, 湯澤 明夏, 王 磊, 杉野 弘和, 鈴鹿 淳, 廣田 聡, 今城 正道, グン 剣萍, 田中 伸哉
日本病理学会会誌, 109, 1, 319, 319, (一社)日本病理学会, 2020年03月
日本語

Emery-Dreifuss型筋ジストロフィーに伴う心不全の1剖検例　　　　　　　　　　　　　　　
五味川 龍, 石田 雄介, 桑原 健, 石垣 隆弘, 谷川 聖, 小田 義崇, 王 磊, 杉野 弘和, 津田 真寿美, 田中 伸哉
日本病理学会会誌, 109, 1, 492, 492, (一社)日本病理学会, 2020年03月
日本語

前立腺癌のGleason pattern評価のためのSemantic segmentationモデル及びRaspberry Pi端末を用いた応用　　　　　　　　　　　　　　　
遠田 建, 伊勢 昂生, 石田 雄介, 桑原 健, 谷川 聖, 小田 義崇, 王 磊, 杉野 弘和, 津田 真寿美, 田中 伸哉
日本病理学会会誌, 109, 1, 496, 496, (一社)日本病理学会, 2020年03月
日本語

新規変異BRAFV601K変異を認める良性脳腫瘍(毛様体性星細胞腫)の一例　　　　　　　　　　　　　　　
榎枝 未紗, 小田 義崇, 津田 真寿美, 飛弾 一利, 杉野 弘和, 谷川 聖, 鈴鹿 淳, 王 磊, 石田 雄介, 田中 伸哉
日本病理学会会誌, 109, 1, 497, 497, (一社)日本病理学会, 2020年03月
日本語

Exosomes containing ErbB2/CRK induce vascular growth in premetastatic niches and promote metastasis of bladder cancer.
Kazuhiko Yoshida, Masumi Tsuda, Ryuji Matsumoto, Shingo Semba, Lei Wang, Hirokazu Sugino, Mishie Tanino, Tsunenori Kondo, Kazunari Tanabe, Shinya Tanaka
Cancer science, 110, 7, 2119, 2132, 2019年07月, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Epithelial-specific histone modification of the miR-96/182 locus targeting AMAP1 mRNA predisposes p53 to suppress cell invasion in epithelial cells.
Haruka Handa, Ari Hashimoto, Shigeru Hashimoto, Hirokazu Sugino, Tsukasa Oikawa, Hisataka Sabe
Cell communication and signaling : CCS, 16, 1, 94, 94, 2018年12月04日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance
A. Hashimoto, S. Hashimoto, H. Sugino, A. Yoshikawa, Y. Onodera, H. Handa, T. Oikawa, H. Sabe
ONCOGENESIS, 5, e259, 2016年09月, ［査読有り］
英語, 研究論文（学術雑誌）

P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance.
Ari Hashimoto, Tsukasa Oikawa, Shigeru Hashimoto, Hirokazu Sugino, Ayumu Yoshikawa, Yutaro Otsuka, Haruka Handa, Yasuhito Onodera, Jin-Min Nam, Chitose Oneyama, Masato Okada, Mitsunori Fukuda, Hisataka Sabe
The Journal of cell biology, 213, 1, 81, 95, 2016年04月11日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Lysophosphatidic acid activates Arf6 to promote the mesenchymal malignancy of renal cancer.
Shigeru Hashimoto, Shuji Mikami, Hirokazu Sugino, Ayumu Yoshikawa, Ari Hashimoto, Yasuhito Onodera, Shotaro Furukawa, Haruka Handa, Tsukasa Oikawa, Yasunori Okada, Mototsugu Oya, Hisataka Sabe
Nature communications, 7, 10656, 10656, 2016年02月08日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Microfluidic active sorting of DNA molecules labeled with single quantum dots using flow switching by a hydrogel sol–gel transition
Haneoka M, Shirasaki Y, Sugino H, Aoki T, Arakawa T, Kazuto Ozaki K, Yoon DH, Ishii N, Iizuka R, Shuichi Shoji S, Funatsu T
Sens. Actuator B-Chem., 159, 1, 314, 320, 2011年11月28日, ［査読有り］
英語, 研究論文（学術雑誌）

Integration in a multilayer microfluidic chip of 8 parallel cell sorters with flow control by sol-gel transition of thermoreversible gelation polymer.
Hirokazu Sugino, Takahiro Arakawa, Yuki Nara, Yoshitaka Shirasaki, Kazuto Ozaki, Shuichi Shoji, Takashi Funatsu
Lab on a chip, 10, 19, 2559, 65, 2010年10月07日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

Microfluidic cell sorter with flow switching triggered by a sol–gel transition of a thermo-reversible gelation polymer
Ozaki K, Sugino H, Shirasaki Y, Aoki T, Arakawa T, Funatsu T, Shoji S
Sens. Actuator B-Chem., 150, 1, 449, 455, 2010年09月, ［査読有り］
英語, 研究論文（学術雑誌）

A microfluidic mammalian cell sorter with thermal gelation polymer solution
Shirasaki Y, Goto M, Sugino H, Arakawa T, Yoon D, Mizuno J, Shoji S, Funatsu T, Ohara O
14th International Conference on Miniaturized Systems for Chemistry and Life Sciences 2010, MicroTAS 2010, 3, 1571, 1573, 2010年, ［査読有り］

Ultimate hydrogel thermal-transition based flow control system for user-friendly particle and cell sorting　　　　　　　　　　　　　　　
Sugino H, Ozaki K, Shirasaki Y, Aoki T, Arakawa T, Yoon DH, Shoji S, Funatsu T
Proceedings of MicroTAS 2010 conference, 224, 226, 2010年, ［査読有り］
英語, 研究論文（国際会議プロシーディングス）

On-chip microfluidic sorting with fluorescence spectrum detection and multiway separation.
Hirokazu Sugino, Kazuto Ozaki, Yoshitaka Shirasaki, Takahiro Arakawa, Shuichi Shoji, Takashi Funatsu
Lab on a chip, 9, 9, 1254, 60, 2009年05月07日, ［査読有り］, ［国際誌］
英語, 研究論文（学術雑誌）

High performance multiple E. Coli cell sorting system using thermosensitive hydrogel and fluoresence spectrum detection　　　　　　　　　　　　　　　
Ozaki K, Sugino H, Arakawa T, Shirasaki Y, Funatsu T, Shoji S
Proceedings of MicroTAS 2009 conference, 1856, 1858, 2009年, ［査読有り］
英語, 研究論文（国際会議プロシーディングス）

ナノバイオテクノロジーの新展開 ナノ・マイクロデバイスによる生体分子の分離・回収と1分子機能解析　　　　　　　　　　　　　　　
船津 高志, 白崎 善隆, 杉野 弘和, 上野 太郎, 上村 想太郎
日本生化学会大会・日本分子生物学会年会合同大会講演要旨集, 81回・31回, 1S9, 5, (公社)日本生化学会, 2008年11月
日本語

High performance multiple biomolecules sorting system
Ozaki K, Sugino H, Arakawa T, Shirasaki Y, Funatsu T, Shoji S
12th International Conference on Miniaturized Systems for Chemistry and Life Sciences - The Proceedings of MicroTAS 2008 Conference, 489, 491, 2008年, ［査読有り］

High performance parallel bioparticle sorter with 3-dimensional PDMS chip　　　　　　　　　　　　　　　
Sugino H, Nara Y, Shirasaki Y, Arakawa T, Shoji S, Funatsu T
Proceedings of MicroTAS 2008 conference, 1184, 1186, 2008年, ［査読有り］
英語, 研究論文（国際会議プロシーディングス）

On-chip cell sorting system using thermoreversible gelation polymer
Yoshitaka Shirasaki, Hirokazu Sugino, Masayasu Tatsuoka, Jun Mizuno, Shuichi Shoji, Takashi Funatsu
IEEE JOURNAL OF SELECTED TOPICS IN QUANTUM ELECTRONICS, 13, 2, 223, 227, 2007年03月, ［査読有り］
英語, 研究論文（学術雑誌）

High through-put parallel biomolecules sorting microsystem with three dimensional PDMS stack
Nara Y, Sugino H, Arakawa T, Shirasaki Y, Funatsu T, Shoji S
TRANSDUCERS and EUROSENSORS '07 - 4th International Conference on Solid-State Sensors, Actuators and Microsystems, 257, 260, 2007年, ［査読有り］

High speed organelles sorting microsystems driven by a single pressure source　　　　　　　　　　　　　　　
Aoki T, Shirasaki Y, Arakawa T, Sugino H, Funatsu T, Shoji S
Proceedings of MicroTAS 2007 conference, 224, 226, 2007年, ［査読有り］
英語, 研究論文（国際会議プロシーディングス）

Parallel bioparticle sorting with TGP solution in 3-dimentional microflow system　　　　　　　　　　　　　　　
Sugino H, Nara Y, Shirasaki Y, Arakawa T, Shoji S, Funatsu T
Proceedings of MicroTAS 2007 conference, 1360, 1362, 2007年, ［査読有り］
英語, 研究論文（国際会議プロシーディングス）

High-speed particles and biomolecules sorting microsystem using thermosensitive hydrogel
Takahiro Arakawa, Yoshitaka Shirasaki, Toshimitsu Izumi, Tokihiko Aoki, Hirokazu Sugino, Takashi Funatsu, Shuichi Shoji
MEASUREMENT SCIENCE AND TECHNOLOGY, 17, 12, 3141, 3146, 2006年12月, ［査読有り］
英語, 研究論文（学術雑誌）

High speed particles and biomolecules sorting microsystem using thermosensitive hydrogel and water two-phase flow
Arakawa T, Izumi T, Teragauchi W, Aoki T, Shirasaki Y, Sugino H, Funatsu T, Shoji S
Proceedings of the IEEE International Conference on Micro Electro Mechanical Systems (MEMS), 2006, 58, 61, 2006年, ［査読有り］

[Classification and Diagnosis of Adult-Type Diffuse Gliomas].
Makoto Ohno, Hirokazu Sugino, No shinkei geka. Neurological surgery, 51, 5, 760, 770, 2023年09月, ［国内誌］
The Central Nervous System Tumours: WHO Classification of Tumours, 5th ed.(WHO CNS5)incorporates molecular pathogenesis with histopathology to classify brain tumors into more biologically and narrowly defined entities. According to this approach, adult-type diffuse gliomas are classified into three tumor types: astrocytoma, IDH-mutant; oligodendroglioma, IDH-mutant and 1p/19q-codeleted; and glioblastoma, IDH-wildtype. Astrocytoma and oligodendroglioma are clearly defined as IDH-mutant tumors, and glioblastoma as an IDH-wildtype tumor. WHO CNS5 provides clear diagnostic criteria framed as "essential and desirable diagnostic criteria," including histopathological and molecular features. In this article, we summarized the diagnostic and grading criteria of adult-type diffuse gliomas, which include histopathological and molecular features. Further, we presented a clinical diagnostic workflow based on the immunohistopathological studies, molecular tests and their surrogate assays, and histopathological features to establish the diagnosis of adult-type diffuse gliomas. We also discussed the limitations of the clinical diagnostic workflow; for instance, some tumors may not fit within this classification provided by this diagnostic flow. Despite these limitations, we are required to utilize the diagnostic criteria and determine optimal treatment in the clinical setting., 日本語

ATXN1::DUX4遺伝子融合を有する中枢神経肉腫の1例　　　　　　　　　　　　　　　
杉野 弘和, 里見 介史, 大野 誠, 久保 崇, 北原 麻衣, 松下 裕子, 市村 幸一, 成田 善孝, 市川 仁, 吉田 朗彦, Brain Tumor Pathology, 40, Suppl., 131, 131, 2023年05月
日本脳腫瘍病理学会, 日本語

ケラチン発現と線維化を示す骨外性粘液型軟骨肉腫は筋上皮腫との鑑別を要する　　　　　　　　　　　　　　　
杉野 弘和, 岩田 慎太郎, 里見 介史, 森 泰昌, 信澤 純人, 永島 宗晃, 谷田部 恭, 市村 幸一, 川井 章, 吉田 朗彦, 日本病理学会会誌, 112, 1, 275, 275, 2023年03月
(一社)日本病理学会, 日本語

ケラチン発現と線維化を示す骨外性粘液型軟骨肉腫は筋上皮腫との鑑別を要する　　　　　　　　　　　　　　　
杉野 弘和, 岩田 慎太郎, 里見 介史, 森 泰昌, 信澤 純人, 永島 宗晃, 谷田部 恭, 市村 幸一, 川井 章, 吉田 朗彦, 日本病理学会会誌, 112, 1, 275, 275, 2023年03月
(一社)日本病理学会, 日本語

ハイドロゲルを用いた中皮腫幹細胞の創出および治療標的分子の探索　　　　　　　　　　　　　　　
加藤 万里絵, 杉野 弘和, 津田 真寿美, 王 磊, 種井 善一, 小田 義崇, 谷川 聖, グン 剣萍, 田中 伸哉, 日本病理学会会誌, 112, 1, 332, 332, 2023年03月
(一社)日本病理学会, 日本語

脊髄capillary hemangiomaの病理像　　　　　　　　　　　　　　　
種井 善一, 津田 真寿美, 小田 義崇, 谷川 聖, 杉野 弘和, 大竹 安史, 今村 博幸, 小柳 泉, 飛騨 一利, 田中 伸哉, 日本病理学会会誌, 111, 1, 264, 264, 2022年03月
(一社)日本病理学会, 日本語

びまん性大細胞型B細胞性リンパ腫の化学療法中に突然死した1剖検例　　　　　　　　　　　　　　　
加藤 万里絵, 種井 善一, 小島 圭祐, 太田 秀一, ウンマ・ハビバ, 小田 義崇, 谷川 聖, 杉野 弘和, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 111, 1, 308, 308, 2022年03月
(一社)日本病理学会, 日本語

内頸動脈瘤術後に急激な意識障害をきたした神経線維腫症1型の一剖検例　　　　　　　　　　　　　　　
京野 里虹, 種井 善一, 岡崎 ななせ, 長内 俊也, 小田 義崇, 谷川 聖, 杉野 弘和, 津田 真寿美, 藤村 幹, 田中 伸哉, 日本病理学会会誌, 111, 1, 356, 356, 2022年03月
(一社)日本病理学会, 日本語

SLEとGood症候群の治療経過中に脳幹障害を来たした一例　　　　　　　　　　　　　　　
黒田 花音, 種井 善一, 岡崎 ななせ, 工藤 彰彦, 阿部 恵, 小田 義崇, 谷川 聖, 杉野 弘和, 矢部 一郎, 田中 伸哉, 日本病理学会会誌, 111, 1, 356, 356, 2022年03月
(一社)日本病理学会, 日本語

甲状腺乳頭癌多発肺転移後に生じた拘束性換気障害の一剖検例　　　　　　　　　　　　　　　
鍵谷 豪太, 種井 善一, 若林 健人, 堀井 洋志, 小田 義崇, 谷川 聖, 杉野 弘和, 谷野 美智枝, 今野 哲, 田中 伸哉, 日本病理学会会誌, 111, 1, 357, 357, 2022年03月
(一社)日本病理学会, 日本語

脊髄capillary hemangiomaの病理像　　　　　　　　　　　　　　　
種井 善一, 津田 真寿美, 小田 義崇, 谷川 聖, 杉野 弘和, 大竹 安史, 今村 博幸, 小柳 泉, 飛騨 一利, 田中 伸哉, 日本病理学会会誌, 111, 1, 264, 264, 2022年03月
(一社)日本病理学会, 日本語

びまん性大細胞型B細胞性リンパ腫の化学療法中に突然死した1剖検例　　　　　　　　　　　　　　　
加藤 万里絵, 種井 善一, 小島 圭祐, 太田 秀一, ウンマ・ハビバ, 小田 義崇, 谷川 聖, 杉野 弘和, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 111, 1, 308, 308, 2022年03月
(一社)日本病理学会, 日本語

内頸動脈瘤術後に急激な意識障害をきたした神経線維腫症1型の一剖検例　　　　　　　　　　　　　　　
京野 里虹, 種井 善一, 岡崎 ななせ, 長内 俊也, 小田 義崇, 谷川 聖, 杉野 弘和, 津田 真寿美, 藤村 幹, 田中 伸哉, 日本病理学会会誌, 111, 1, 356, 356, 2022年03月
(一社)日本病理学会, 日本語

SLEとGood症候群の治療経過中に脳幹障害を来たした一例　　　　　　　　　　　　　　　
黒田 花音, 種井 善一, 岡崎 ななせ, 工藤 彰彦, 阿部 恵, 小田 義崇, 谷川 聖, 杉野 弘和, 矢部 一郎, 田中 伸哉, 日本病理学会会誌, 111, 1, 356, 356, 2022年03月
(一社)日本病理学会, 日本語

甲状腺乳頭癌多発肺転移後に生じた拘束性換気障害の一剖検例　　　　　　　　　　　　　　　
鍵谷 豪太, 種井 善一, 若林 健人, 堀井 洋志, 小田 義崇, 谷川 聖, 杉野 弘和, 谷野 美智枝, 今野 哲, 田中 伸哉, 日本病理学会会誌, 111, 1, 357, 357, 2022年03月
(一社)日本病理学会, 日本語

レンバチニブ使用後にConversion surgeryを施行した肝細胞癌術後多発肺転移の一例
佐野峻司, 神山俊哉, 柿坂達彦, 折茂達也, 長津明久, 旭火華, 相山健, 数井啓蔵, 正村裕紀, 植木伸也, 坂本譲, 白川智沙斗, 蒲池浩文, 杉野弘和, 三橋智子, 服部淳夫, 武冨紹信, 日本外科学会定期学術集会(Web), 122nd, 2022年

レンバチニブによりconversion surgeryが可能となった肝細胞癌術後多発肺転移の一例
脇坂和貴, 神山俊哉, 柿坂達彦, 折茂達也, 長津明久, 旭火華, 相山健, 佐野峻司, 数井啓蔵, 正村裕紀, 植木伸也, 坂本譲, 杉野弘和, 三橋智子, 服部淳夫, 武冨紹信, 日本肝がん分子標的治療研究会プログラム・抄録集, 26th, 2022年

ハイドロゲルを用いた新規髄膜腫治療標的分子の検討(Analysis of novel therapeutic target for meningioma using hydrogel)　　　　　　　　　　　　　　　
小田 義崇, 津田 真寿美, 湯澤 明夏, 王 磊, Umma Habiba, 杉野 弘和, 種井 善一, グン 剣萍, 田中 伸哉, 日本病理学会会誌, 110, 2, 110, 110, 2021年10月
(一社)日本病理学会, 英語

脊髄capillary hemangiomaの臨床病理学的特徴　　　　　　　　　　　　　　　
種井 善一, 津田 真寿美, 谷川 聖, 杉野 弘和, 石田 雄介, 大竹 安史, 今村 博幸, 小柳 泉, 飛騨 一利, 田中 伸哉, Brain Tumor Pathology, 38, Suppl., 119, 119, 2021年05月
日本脳腫瘍病理学会, 日本語

成人型Krabbe病の一剖検例　　　　　　　　　　　　　　　
佐々木 美羽, 江端 美織, 小田 義崇, 濱内 朗子, 谷川 聖, 種井 善一, 杉野 弘和, 石田 雄介, 佐光 一也, 田中 伸哉, 日本病理学会会誌, 110, 1, 379, 379, 2021年03月
(一社)日本病理学会, 日本語

レンバチニブ使用後にConversion surgeryを施行した肝細胞癌術後多発肺転移の1例
佐野峻司, 神山俊哉, 柿坂達彦, 折茂達也, 長津明久, 旭火華, 相山健, 蒲池浩文, 武冨紹信, 数井啓蔵, 正村裕紀, 植木伸也, 坂本譲, 白川智沙斗, 杉野弘和, 三橋智子, 服部惇夫, 北海道外科雑誌, 66, 2, 2021年

バイオマテリアルによる肝癌幹細胞の新規誘導法の開発とその解析　　　　　　　　　　　　　　　
谷 道夫, 津田 真寿美, 鈴鹿 淳, 王 磊, 杉野 弘和, 谷川 聖, 石田 雄介, グン 剣萍, 田中 伸哉, 武冨 紹信, 日本外科学会定期学術集会抄録集, 120回, DP, 6, 2020年08月
(一社)日本外科学会, 日本語

バイオマテリアルによる肝癌幹細胞の新規誘導法の開発とその解析　　　　　　　　　　　　　　　
谷 道夫, 津田 真寿美, 鈴鹿 淳, 王 磊, 杉野 弘和, 谷川 聖, 石田 雄介, グン 剣萍, 田中 伸哉, 武冨 紹信, 日本外科学会定期学術集会抄録集, 120回, DP, 6, 2020年08月
(一社)日本外科学会, 日本語

Emery-Dreifuss型筋ジストロフィーに伴う心不全の1剖検例　　　　　　　　　　　　　　　
五味川 龍, 石田 雄介, 桑原 健, 石垣 隆弘, 谷川 聖, 小田 義崇, 王 磊, 杉野 弘和, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 109, 1, 492, 492, 2020年03月
(一社)日本病理学会, 日本語

前立腺癌のGleason pattern評価のためのSemantic segmentationモデル及びRaspberry Pi端末を用いた応用　　　　　　　　　　　　　　　
遠田 建, 伊勢 昂生, 石田 雄介, 桑原 健, 谷川 聖, 小田 義崇, 王 磊, 杉野 弘和, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 109, 1, 496, 496, 2020年03月
(一社)日本病理学会, 日本語

新規変異BRAFV601K変異を認める良性脳腫瘍(毛様体性星細胞腫)の一例　　　　　　　　　　　　　　　
榎枝 未紗, 小田 義崇, 津田 真寿美, 飛弾 一利, 杉野 弘和, 谷川 聖, 鈴鹿 淳, 王 磊, 石田 雄介, 田中 伸哉, 日本病理学会会誌, 109, 1, 497, 497, 2020年03月
(一社)日本病理学会, 日本語

病理IT化、情報化とAI研究 病理診断と人工知能 スタートアップから脳腫瘍への応用まで　　　　　　　　　　　　　　　
石田 雄介, 桑原 健, 小田 義崇, 谷川 聖, 杉野 弘和, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 108, 1, 192, 192, 2019年04月
(一社)日本病理学会, 日本語

小児下顎骨に生じたnodular fasciitisの1例　　　　　　　　　　　　　　　
石田 雄介, 伊勢 昂生, 小田 義崇, 谷川 聖, 杉野 弘和, 嶋崎 康相, 藤森 真樹, 松田 彩, 北村 哲也, 田中 伸哉, 日本病理学会会誌, 108, 1, 340, 340, 2019年04月
(一社)日本病理学会, 日本語

解剖で偶然見つかった無症候性胸髄内神経鞘腫の一例　　　　　　　　　　　　　　　
有田 梨乃, 谷川 聖, 津田 真寿美, 石田 雄介, 杉野 弘和, 田中 伸哉, 日本病理学会会誌, 108, 1, 459, 459, 2019年04月
(一社)日本病理学会, 日本語

髄膜腫におけるTERTプロモーター遺伝子変異の検討　　　　　　　　　　　　　　　
久世 瑞穂, 小田 義崇, 津田 真寿美, 湯澤 明夏, 谷川 聖, 杉野 弘和, 石田 雄介, 田中 伸哉, 日本病理学会会誌, 108, 1, 463, 463, 2019年04月
(一社)日本病理学会, 日本語

初回治療から18年後に生じた多臓器進展を伴うホジキンリンパ腫の一剖検例　　　　　　　　　　　　　　　
五味川 龍, 杉野 弘和, 白鳥 聡一, 石田 雄介, 王 磊, 畑中 佳奈子, 松野 吉宏, 豊嶋 崇徳, 田中 伸哉, 日本病理学会会誌, 108, 1, 453, 453, 2019年04月
(一社)日本病理学会, 日本語

バイオマテリアルによる肝癌幹細胞の新規誘導法　　　　　　　　　　　　　　　
谷 道夫, 津田 真寿美, 鈴鹿 淳, 王 磊, 杉野 弘和, 谷川 聖, 石田 雄介, グン 剣萍, 田中 伸哉, 武冨 紹信, 日本外科学会定期学術集会抄録集, 119回, PS, 6, 2019年04月
(一社)日本外科学会, 日本語

馬尾原発の髄外性形質細胞腫の1例　　　　　　　　　　　　　　　
小田 義崇, 杉野 弘和, 小柳 泉, 谷川 聖, 石田 雄介, 津田 真寿美, 田中 伸哉, Brain Tumor Pathology, 35, Suppl., 177, 177, 2018年09月
日本脳腫瘍病理学会, 日本語

神経再生工学における両電荷を有するハイドロゲルの開発　　　　　　　　　　　　　　　
谷川 聖, 仙葉 慎吾, 津田 真寿美, 王 磊, 谷野 美智枝, 石田 雄介, 杉野 弘和, 鈴鹿 淳, 田中 伸哉, 日本病理学会会誌, 107, 1, 329, 329, 2018年04月
(一社)日本病理学会, 日本語

悪性神経膠腫におけるIDH1遺伝子変異による放射線照射後変化の解析(Analysis of the effect of IDH1 mutation on the radiosensitivity in malignant glioma)　　　　　　　　　　　　　　　
北崎 アリサ, 谷野 美智枝, 九笹 めい, 杉野 弘和, 王 磊, 石田 雄介, 津田 真寿美, 五十嵐 香織, 曽我 朋義, 田中 伸哉, 日本病理学会会誌, 107, 1, 379, 379, 2018年04月
(一社)日本病理学会, 英語

脳腫瘍組織像の画像解析と遺伝子プロファイルに対応したDeep-Learning法の応用　　　　　　　　　　　　　　　
石田 雄介, 杉野 弘和, 谷野 美智枝, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 107, 1, 380, 380, 2018年04月
(一社)日本病理学会, 日本語

悪性中皮腫におけるOTUB1の役割　　　　　　　　　　　　　　　
九笹 めい, 谷野 美智枝, 北崎 アリサ, 杉野 弘和, 石田 雄介, 王 磊, 津田 真寿美, 高澤 啓, 平野 博嗣, 田中 伸哉, 日本病理学会会誌, 107, 1, 406, 406, 2018年04月
(一社)日本病理学会, 日本語

脳死肝移植後に感染源不明の敗血症を繰り返し死亡した一例の死後画像および病理解剖所見　　　　　　　　　　　　　　　
伊勢 昂生, 山下 たんぽぽ, 石田 雄介, 桑原 健, 川村 典生, 菊池 穏香, 杉野 弘和, 谷野 美智枝, 津田 真寿美, 田中 伸哉, 日本病理学会会誌, 107, 1, 530, 530, 2018年04月
(一社)日本病理学会, 日本語

末梢性T細胞リンパ腫の剖検時に見出された硬化性胸腺腫の一例　　　　　　　　　　　　　　　
飯田 圭祐, 植田 沙也加, 杉野 弘和, 曾澤 佳昭, 谷野 美智枝, 石田 雄介, 王 磊, 田中 伸哉, 日本病理学会会誌, 107, 1, 533, 533, 2018年04月
(一社)日本病理学会, 日本語

中枢神経系に生じたメトトレキサート関連リンパ増殖性疾患の一例　　　　　　　　　　　　　　　
杉野 弘和, 佐藤 憲市, 笠井 康弘, 孫 慧, 石田 雄介, 谷野 美智枝, 津田 真寿美, 松野 吉宏, 田中 伸哉, 日本病理学会会誌, 107, 1, 449, 449, 2018年04月
(一社)日本病理学会, 日本語

悪性中皮腫におけるOTUB1の発現　　　　　　　　　　　　　　　
九笹 めい, 谷野 美智枝, 北崎 アリサ, 杉野 弘和, 石田 雄介, 王 磊, 津田 真寿美, 高澤 啓, 平野 博嗣, 田中 伸哉, 日本癌学会総会記事, 76回, P, 3277, 2017年09月
日本癌学会, 英語

悪性神経膠腫においてIDH1遺伝子変異は放射線照射後のアポトーシスを亢進する　　　　　　　　　　　　　　　
北崎 アリサ, 谷野 美智枝, 九笹 めい, 杉野 弘和, 王 磊, 石田 雄介, 仙葉 慎吾, 津田 真寿美, 五十嵐 香織, 曽我 朋義, 田中 伸哉, 日本癌学会総会記事, 76回, P, 3323, 2017年09月
日本癌学会, 英語

多形黄色星細胞腫におけるBRAF遺伝子変異(BRAF V600E)とp16の発現の検討　　　　　　　　　　　　　　　
谷野 美智枝, 南條 博, 津田 真寿美, 杉野 弘和, 王 磊, 石田 雄介, 田中 伸哉, 日本癌学会総会記事, 76回, P, 3317, 2017年09月
日本癌学会, 英語

EZH2発現亢進により創出されるArf6を中心とした間葉浸潤に特化した分子装置は腎癌の予後不良に関与する(EZH2 generates Arf6-based mesenchymal invasion machinery that is central to poor prognosis of renal cancer)　　　　　　　　　　　　　　　
橋本 茂, 杉野 弘和, 橋本 あり, 吉河 歩, 及川 司, 半田 悠, 大家 基嗣, 三上 修治, 佐邊 壽孝, 日本癌学会総会記事, 73回, J, 2075, 2014年09月
日本癌学会, 英語

乳癌において変異p53がリガンド反応性の間葉型浸潤分子装置を創出する機序(TP53 alterations generate Arf6-based mesenchymal invasion pathway that is activated by RTKs and TGFβ1 in breast cancer)　　　　　　　　　　　　　　　
橋本 あり, 橋本 茂, 杉野 弘和, 吉河 歩, 及川 司, 小野寺 康仁, 半田 悠, 大塚 勇太郎, 岩見 昴亮, 小根山 千歳, 岡田 雅人, 福田 光則, 佐邊 壽孝, 日本癌学会総会記事, 73回, J, 2077, 2014年09月
日本癌学会, 英語

ArfGAPs: Not only for the termination
Shigeru Hashimoto, Ari Hashimoto, Hirokazu Sugino, Ayumu Yoshikawa, Haruka Handa, Masanao Yoshino, Yutaro Otsuka, Hisataka Sabe, Ras Superfamily Small G Proteins: Biology and Mechanisms 2: Transport, 253, 274, 2014年05月01日

癌放射線治療への分子生物学的アプローチ 変異p53が放射線抵抗性に根幹的な間葉型浸潤経路を創出する機構(Toward the improvement of radiotherapy: Approaches from the molecular biological point of view Mechanisms by which oncogenic mutant-p53 generates mesenchymal invasive pathway pivotal to a radiation resis　　　　　　　　　　　　　　　
佐邊 壽孝, 橋本 あり, 橋本 茂, 小野寺 康仁, 及川 司, Nam Jin-Min, 小根山 千歳, 杉野 弘和, 吉河 歩, 大塚 勇太郎, 半田 悠, 芳野 正修, 岡田 雅人, 日本癌学会総会記事, 72回, 64, 64, 2013年10月
日本癌学会, 英語

細胞が持つリサイクルシステム研究の新展開 p53変異によるGEP100-Arf6-AMAP1経路の活性化と乳癌の浸潤形質獲得　　　　　　　　　　　　　　　
橋本 茂, 橋本 あり, 小根山 千歳, 吉河 歩, 杉野 弘和, 半田 悠, 芳野 正修, 大塚 勇太郎, 小野寺 康仁, 岡田 雅人, 佐邊 壽孝, 日本生化学会大会プログラム・講演要旨集, 86回, 2S04a, 3, 2013年09月
(公社)日本生化学会, 日本語

EZH2によるmiR-203発現抑制が乳癌浸潤に中枢的であるArf6-AMAP1経路創出に関わる(EZH2-mediated downregulation of miR-203 generates the Arf6-AMAP1 pathway pivotal for breast cancer invasiveness)　　　　　　　　　　　　　　　
杉野 弘和, 橋本 茂, 橋本 あり, 吉河 歩, 半田 悠, 佐邊 壽孝, 日本癌学会総会記事, 71回, 87, 87, 2012年08月
日本癌学会, 英語

がんの浸潤・転移に関与するGEP100-Arf6-AMAP1経路とc-Metシグナルとの相互作用(GAB1 links c-Met signaling with GEP100-Arf6-AMAP1 pathway to promote breast cancer invasiveness)　　　　　　　　　　　　　　　
吉河 歩, 橋本 茂, 橋本 あり, 杉野 弘和, 大塚 勇太郎, 味藤 静, 半田 悠, 佐邊 壽孝, 日本癌学会総会記事, 71回, 87, 87, 2012年08月
日本癌学会, 英語

乳癌浸潤に中枢的なArf6経路は変異p53により創出される(Mutant-p53 generates GEP100-Arf6-AMAP1 pathway to promote breast cancer cell invasiveness in response to TGFbeta1)　　　　　　　　　　　　　　　
橋本 あり, 橋本 茂, 吉河 歩, 杉野 弘和, 半田 悠, 味藤 静, 佐藤 宏紀, 大塚 勇太郎, 芳野 日南子, 南 ジンミン, 小野寺 康仁, 佐邊 壽孝, 日本癌学会総会記事, 71回, 399, 399, 2012年08月
日本癌学会, 英語

変異p53が癌浸潤転移シグナル経路を創出し活性化する
橋本あり, 橋本茂, 吉河歩, 杉野弘和, 半田悠, 木下留美子, 畑中佳奈子, 三上修治, 谷野美智枝, 味藤静, 佐藤宏紀, 大塚勇太郎, 芳野日南子, 加戸由加里, NAM Jin‐Min, 小野寺康仁, 田中伸哉, 白土博樹, 佐邊壽孝, 日本分子生物学会年会プログラム・要旨集(Web), 35th, 2W10II-1 (WEB ONLY), 2012年
日本語

Arf6活性化による乳癌浸潤形質獲得過程におけるエピジェネティック制御の関与
橋本茂, 杉野弘和, 橋本あり, 吉河歩, 大塚勇太郎, 芳野正修, 半田悠, 佐邊壽孝, 日本分子生物学会年会プログラム・要旨集(Web), 35th, 2P-0166 (WEB ONLY), 2012年
日本語

変異p53はArf6活性化経路を介した浸潤獲得形質に必須である(Mutant p53 is essential for TGFβ1-induced breast cancer cell invasiveness via activation of GEP100-Arf6-AMAP1 pathway)　　　　　　　　　　　　　　　
橋本 あり, 橋本 茂, 大塚 勇太郎, 吉河 歩, 杉野 弘和, 半田 悠, 南 ジンミン, 佐藤 宏紀, 福田 諭, 小野寺 康仁, 佐邊 壽孝, 日本癌学会総会記事, 70回, 38, 38, 2011年09月
日本癌学会, 英語

TGFβ及び低酸素によるArf6活性化を介した癌浸潤形質獲得におけるエピジェネティック因子の関与(EZH2 is essential to Arf6 activation necessary for TGFβ1- and hypoxia-induced invasiveness of breast cancer cells)　　　　　　　　　　　　　　　
橋本 茂, 橋本 あり, 小野寺 康仁, 大塚 勇太郎, 吉河 歩, 杉野 弘和, 半田 悠, 佐藤 宏紀, 福田 諭, 毛受 暁史, 佐邊 壽孝, 日本癌学会総会記事, 70回, 77, 77, 2011年09月
日本癌学会, 英語

TGFβ1による癌的EMTにおけるGEP100-Arf6-AMAP1シグナルの機能解析(HGFR/c-Met-mediated activation of GEP100-Arf6-AMAP1 pathway is an integral part for TGFβ-induced cancerous EMT and invasiveness)　　　　　　　　　　　　　　　
橋本 あり, 橋本 茂, 大塚 勇太郎, 佐藤 宏紀, 杉野 弘和, 吉河 歩, 梅本 勉, 小野寺 康仁, 福田 諭, 佐邊 壽孝, 日本細胞生物学会大会講演要旨集, 63回, 151, 151, 2011年05月
(一社)日本細胞生物学会, 英語

3J1036 温度感受性ポリマーを使ったマイクロ流体ソーティングシステムによる蛍光性ナノ粒子の分離(3J バイオエンジニアリング1,日本生物物理学会第49回年会)
Haneoka Mai, Sugino Hirokazu, Shirasaki Yoshitaka, Aoki Tokihiko, Arakawa Takahiro, Dong Hyun Yoon, Shoji Shuichi, Funatsu Takashi, 生物物理, 51, S140, S141, 2011年
一般社団法人 日本生物物理学会, 英語

2P340 温度感受性ポリマーを使ったマイクロ流体ソーティングシステムによる蛍光性ナノ粒子の分離(バイオエンジニアリング,第48回日本生物物理学会年会)
Haneoka Mai, Sugino Hirokazu, Shirasaki Yoshitaka, Arakawa Takahiro, Yoon Dong Hyun, Shoji Shuichi, Funatsu Takasi, 生物物理, 50, 2, S142, 2010年
一般社団法人 日本生物物理学会, 英語

8-Parallel Bioparticle Sorter with a Multilayer PDMS Chip
Sugino Hirokazu, Ozaki Kazuto, Arakawa Takahiro, Shirasaki Yoshitaka, Nara Yuki, Shoji Shuichi, Funatsu Takashi, BIOPHYSICAL JOURNAL, 98, 3, 194A, 194A, 2010年01月
英語, 研究発表ペーパー・要旨（国際会議）

2TA5-07 マイクロ流体デバイスを用いた8並列型ソーター(バイオエンジニアリング,第47回日本生物物理学会年会)
Sugino Hirokazu, Ozaki Kazuto, Arakawa Takahiro, Shirasaki Yoshitaka, Nara Yuki, Shoji Shuichi, Funatsu Takashi, 生物物理, 49, S46, 2009年
一般社団法人 日本生物物理学会, 英語

1P-325 PDMSチップのワンステップ3次元鋳造加工と温度感受性ハイドロゲルによる哺乳類細胞の分離(バイオエンジニアリング,第46回日本生物物理学会年会)
Shirasaki Yoshitaka, Arakawa Takahiro, Sugino Hirokazu, Mizuno Jun, Shoji Shuichi, Funatsu Takashi, Ohara Osamu, 生物物理, 48, S72, 2008年
一般社団法人 日本生物物理学会, 英語

3P350 マイクロ流体チップを用いたオルガネラソーティング(その他,ポスター発表,第45回日本生物物理学会年会)
杉野 弘和, 青木 時彦, 白崎 善隆, 荒川 貴博, 庄子 習一, 船津 高志, 生物物理, 47, S290, 2007年
一般社団法人 日本生物物理学会, 英語

2P485 Development of an on-chip biomolecule parallel sorter using thermoreversible gelation polymer(51. New methods and tools (II),Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)
Sugino Hirokazu, Nara Yuki, Shirasaki Yoshitaka, Arakawa Takahiro, Syoji Syuichi, Funatsu Takashi, 生物物理, 46, 2, S417, 2006年
一般社団法人 日本生物物理学会, 英語

3P325 温感性ハイドロゲルを用いた多分岐マイクロソーターの開発(バイオエンジニアリング))
杉野 弘和, 白崎 善隆, 辰岡 正康, 筒井 謙, 水野 潤, 庄子 習一, 船津 高志, 生物物理, 45, S285, 2005年
一般社団法人 日本生物物理学会, 日本語

2P297 温感性ハイドロゲルを用いたマイクロソーターの改良(バイオエンジニアリング)
杉野 弘和, 白崎 善隆, 和田 恭雄, 筒井 謙, 江面 知彦, 庄子 習一, 船津 高志, 生物物理, 44, S184, 2004年
一般社団法人 日本生物物理学会, 日本語

ArfGAPs: Not Only for the Termination.　　　　　　　　　　　　　　　
Hashimoto S, Hashimoto A, Sugino H, Yoshikawa A, Handa H, Yoshino M, Otsuka Y, Sabe H, RAS Superfamily Small G Proteins: Biology and Mechanisms 2
Springer, 2014年, ［共著］

乳癌レビュー 2012　　　　　　　　　　　　　　　
橋本あり, 杉野弘和, 橋本茂, 佐邊壽孝, EMT –基礎的観点から
メディカルレビュー社, 2011年, ［共著］